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The human nucleotide binding and oligomerization
domain (NOD)-containing protein family consists of
some 25 members related to the Apaf-1/Ced-4 family
of apoptosis regulators and certain plant disease-
resistance genes (Inohara et al., 2004). One member,
NOD2 (CARD15), has gained recent prominence
through its association with increased susceptibility
to several clinically important human inflammatory
diseases, especially Crohn’s disease (CD). NOD2 is a
cytoplasmic molecule involved in sensing microbial
cell wall components and regulating inflammatory
processes and apoptosis. This review focuses on re-
cent insights into the functions of normal and variant
NOD2 proteins and the pathogenetic mechanisms un-
derlying NOD2-associated inflammatory diseases.
NOD2 Mutations and Human Disease
CD, one of two major forms of inflammatory bowel dis-
ease (IBD) affecting some one million people in North
America and Europe alone, is characterized by diar-
rhea, abdominal pain, fever, and weight loss due to
chronic, relapsing intestinal inflammation. CD is most
frequently diagnosed in young adults and is relatively
uncommon in children younger than 10 years (Mamula
et al., 2003). Familial association and twin studies had
suggested a genetic contribution to the etiology of CD,
although diverse environmental factors are also likely
to play a critical role in disease development. Detailed
linkage analyses in affected families using genome-
wide scanning have revealed several genetic loci,
IBD1–IBD8, that show significant association with CD
(Brant and Shugart, 2004). Fine mapping of the IBD1
locus by positional cloning and candidate gene analy-
sis has identified NOD2 as the first gene to be firmly
associated with CD susceptibility in North American
and European populations (Hugot et al., 2001; Ogura et
al., 2001a). Of the more than 60 reported NOD2 se-
quence variants, three main variants, R702W, G908R,
and 1007fs, exhibit the strongest CD association (Ah-
mad et al., 2002). In particular, the frameshift mutation
1007fs (also termed 3020insC, based on the mutated
nucleotide position relative to the human NOD2a iso-
form as the cDNA sequence reference) shows the most
consistent association with CD across multiple studies*Correspondence: leckmann@ucsd.edu (L.E.); karinoffice@ucsd.
edu (M.K.)and population groups (Economou et al., 2004). All
three variants alter the C-terminal third of the gene
product, and are within or close to a region of leucine-
rich repeats (LRRs) thought to be involved in ligand rec-
ognition (Figure 1). CD-associated mutations were not
found in the 5# end of the gene, a region that codes for
two protein-protein interaction domains. Importantly,
no mutations that prevent production of a nearly full-
length NOD2 protein have been identified.
Individuals with one of the three major disease-asso-
ciated alleles have a 2- to 4-fold increased risk of de-
veloping CD, whereas homozygous or compound het-
erozygous carriers have a 15- to 40-fold increase in risk
(Economou et al., 2004). These associations show a
strong gene dosage effect and have been interpreted
as being consistent with a recessive disease pheno-
type, although the modest but significant increase in
disease risk in heterozygotes would suggest a more
complex interpretation, perhaps involving dominant
and recessive aspects in the functions of the variant
NOD2 proteins. Despite their strong association with
CD, mutated NOD2 alleles are neither sufficient nor
necessary for the development of CD, since they occur
in healthy individuals, with estimates most commonly
around 0.5%–2% in the general population, and 60%–
70% of CD patients show no NOD2 mutations (Ahmad
et al., 2002; Economou et al., 2004). Therefore, mutant
NOD2 is a predisposing risk factor for CD, which is
likely to act in synergy with other factors, both genetic
and environmental, in causing disease. In contrast to
CD, NOD2 mutations are not found in patients with ul-
cerative colitis, the other major form of IBD (Hugot et
al., 2001; Ogura et al., 2001a).
Different NOD2 mutations are associated with in-
creased susceptibility to psoriatic arthritis (Rahman et
al., 2003), a severe form of psoriasis that occurs in up
to 30% of psoriatic patients, and with Blau syndrome,
a rare autosomal dominant disorder characterized by
early-onset granulomatous arthritis, uveitis, and skin
rash (Miceli-Richard et al., 2001). Interestingly, the Blau
syndrome-associated mutations affect the central nu-
cleotide binding domain of NOD2, rather than the C-ter-
minal portion, suggesting an important difference in the
molecular pathogenesis of Blau syndrome and CD. Fur-
thermore, recent studies have suggested a possible as-
sociation between NOD2 mutations and the develop-
ment of colon and breast cancer (Huzarski et al., 2005;
Kurzawski et al., 2004). Such an association was not
found in other studies (Alhopuro et al., 2004), so the
ultimate significance of these observations remains to
be established.
Functions of Normal NOD2
NOD2 is composed of two N-terminal caspase recruit-
ment domains (CARDs), a nucleotide binding and oligo-
merization domain, and ten C-terminal LRRs (Figure 1).
It is expressed constitutively in myeloid cells, particu-
larly macrophages, neutrophils, and dendritic cells
(Ogura et al., 2001b), as well as in Paneth cells in the
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PFigure 1. Structure of NOD2
vNOD2 has a tripartite structure, with two caspase recruitment do-
mains (CARD) at the N-terminal end, a centrally located nucleotide a
binding and oligomerization domain (NOD), and a C-terminal set of 2
ten leucine-rich repeats (LRRs). The three major mutations associ- m
ated with CD affect the C-terminal portion at sites that are depicted w
by arrows.
g
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wsmall intestine, which are of epithelial origin (Ogura et
aal., 2003; Lala et al., 2003). NOD2 expression can be
ginduced by the proinflammatory cytokines TNF-α and
sIFN-γ in cultured intestinal epithelial cells (Rosenstiel et
nal., 2003). Accordingly, its expression in enterocytes is
alow under normal but elevated under inflammatory con-
Iditions (Rosenstiel et al., 2003).
iNOD2 is a cytoplasmic protein that serves as a mi-
ocrobial sensor, as it is involved in recognition of mu-
nramyl dipeptide (MDP), a peptidoglycan motif present
rin the cell wall of gram-positive and gram-negative bac-
mteria (Girardin et al., 2003; Inohara et al., 2003). Al-
Pthough NOD2 is commonly referred to as the MDP re-
iceptor, direct and specific binding of MDP to NOD2 has
not been demonstrated to date. Until then, the mecha-
nism of MDP recognition remains a mystery. NOD2 can A
Nassociate through its CARD domains with the RIP2/
RICK protein kinase, leading to activation of IκB kinase t
t(IKK) and NF-κB and subsequent induction of genes
encoding proinflammatory cytokines (Abbott et al., t
t2004). NOD2 can activate NF-κB by itself in a dose-
dependent manner, but this function is strongly en- f
thanced upon incubation of NOD2-expressing cells with
MDP (Girardin et al., 2003; Inohara et al., 2003). In epi- e
pthelial cells, NOD2 may also interact with GRIM-19
(Barnich et al., 2005), a subunit of the NADH:ubiquinone e
koxidoreductase complex (Fearnley et al., 2001) and a
suppressor of STAT3 transcriptional activity (Zhang et m
aal., 2003). This interaction contributes to NOD2-depen-
dent NF-κB activation in these cells (Barnich et al., o
a2005), although suppression of STAT3 activity may aug-
ment programmed cell death, of which NF-κB is a po- p
Itent inhibitor (Karin and Lin, 2002). Furthermore, NOD2
has been reported to interact with TGFβ-activated ki- 1
cnase 1, TAK1 (Chen et al., 2004), which plays a role
in IL-1- and TNF-α-induced IKK and NF-κB activation f
b(Takaesu et al., 2003). Normal TAK1 function is required
for NOD2-dependent NF-κB activation, yet NOD2 ap- f
spears to inhibit the ability of TAK1 to activate NF-κB in
the absence of RIP2 (Chen et al., 2004). Clearly, much l
cremains to be learned about the physiologically rele-
vant mechanisms of NOD2 signal transduction. t
fAlthough the ability of NOD2 to act as a microbial
sensor is well recognized and several potential signal- I
ling pathways involved in inflammation and innate im-
munity linked to NOD2 activation were identified in cul- t
Ttured cells, the physiological functions of NOD2 are
less well understood. Gene-targeted mice deficient for s
NNOD2 were reported to be healthy and fertile, indicatinghat the protein has no critical developmental functions
Kobayashi et al., 2005; Pauleau and Murray, 2003). Very
oung Nod2 knockout mice were more resistant to sys-
emic challenge with a high dose of bacterial endotoxin
LPS), whereas adult knockout mice showed a smaller
ifference in LPS susceptibility (Kobayashi et al., 2005;
auleau and Murray, 2003). However, these mice sur-
ived systemic challenge with a combination of LPS
nd MDP better than wild-type mice (Kobayashi et al.,
005). Furthermore, adult Nod2 knockout mice were
ore susceptible to oral, but not systemic, infection
ith the enteric bacterial pathogen Listeria monocyto-
enes. This was paralleled by decreased expression of
he Paneth cell α-defensins, Defcr4 and Defcr-rs10,
hich are antimicrobial peptides that can kill Listeria
nd other enteric bacteria (Kobayashi et al., 2005). To-
ether, these data suggest that normal NOD2 mediates
ystemic responses to the bacterial cell wall compo-
ent MDP and can play a role in intestinal host defense
gainst at least one enteric bacterial pathogen, Listeria.
n support of the latter, transfection of normal NOD2
nto intestinal epithelial cells was shown to limit uptake
r growth of another invasive enteric bacteria, Salmo-
ella, suggesting that NOD2 can exert, directly or indi-
ectly, antimicrobial functions in epithelial cells (Hisa-
atsu et al., 2003). However, with the exception of
aneth cells, NOD2 is not normally expressed in the
ntestinal epithelium.
ctivities of NOD2 Variants
OD2 mutations associated with CD are confined to
he LRR domain and were reported to abolish the ability
o sense MDP and activate NF-κB in transient transfec-
ion experiments (Bonen et al., 2003). This suggests
hat the CD-associated mutations result in a loss-of-
unction phenotype. Consistently, most of these muta-
ions appear to act in a recessive manner (Economou
t al., 2004). Furthermore, monocytes isolated from CD
atients carrying the 1007fs mutation were reported to
xhibit defects in production of proinflammatory cyto-
ines, TNF-α, IL-6, and IL-8, as well as the anti-inflam-
atory cytokine IL-10 (Netea et al., 2004; van Heel et
l., 2005). However, CD is associated with the presence
f epithelial cells and lamina propria macrophages with
ctivated NF-κB in their nuclei, and these cells overex-
ress products of NF-κB target genes including TNF-α,
L-1β, and IL-6 under inflamed conditions (Rogler et al.,
998; Schreiber et al., 1998). The studies with cultured
ells, whose results were opposite to those obtained
rom analysis of tissue samples, employed peripheral
lood monocytes isolated from patients with active in-
lammatory disease (Netea et al., 2004). Thus, one pos-
ible explanation for this discrepancy is that after pro-
onged exposure to high levels of proinflammatory
ytokines and bacterial products such as endotoxin in
he circulation, these monocytes may have become re-
ractory to further stimulation (Caradonna et al., 2000).
mportantly, the presence of elevated TNF-α and IL-1
evels in clinical samples isolated from CD patients and
he responsiveness of many of these patients to anti-
NF-α therapy appear to be inconsistent with the pre-
umed loss of NF-κB inducibility by the CD-associated
OD2 variants. Several hypotheses were advanced to
Review
663reconcile these observations and provide a mecha-
nistic explanation for the apparent inflammation-pro-
moting functions of the variant NOD2 proteins. They
can be divided conceptually into those advocating that
mutant NOD2 is defective in performing critical func-
tions required for limiting inflammation (“loss-of-func-
tion”), and those proposing that the variant proteins di-
rectly activate proinflammatory signaling pathways
(“gain-of-function”). It is important to note that these
hypotheses are not mutually exclusive and may be valid
in combination.
Impaired Epithelial Defense
Transfection of wild-type, but not mutant, NOD2 into
intestinal epithelial cells inhibited uptake or growth of
invasive bacteria (Hisamatsu et al., 2003). This sug-
gests that the normal protein exerts antimicrobial activ-
ity, whereas variants associated with CD are defective
in this function (Figure 2). This loss of NOD2 function
may be related to the inability to activate NF-κB and,
hence, the expression of potential NF-κB-dependent
anti-microbial gene products such as β-defensin 2 orFigure 2. Hypotheses for Explaining the Functions of CD-Associated NOD2 Variants
Three potential hypotheses were provided to explain the mechanisms by which NOD2 variants can promote intestinal inflammation. The top
row shows the functions of normal NOD2 (green), whereas the bottom row depicts those of mutant NOD2 (NOD2m, blue). Hypothesis I
(“Defective epithelial defense,” left column) envisions that normal NOD2 expressed in Paneth cells, or enterocytes upon stimulation, contrib-
utes to epithelial host defense against enteric bacteria (red rods) through induction of α-defensins (Def), which are released by Paneth cells
and kill luminal microbes (gray rods with dashed outline), or through other unknown mechanisms in enterocytes. NOD2 variants fail to activate
these defense mechanisms, leading to increased bacterial burden followed by mucosal inflammation. Hypothesis II (“IL-12 dysregulation,”
middle column) suggests that normal NOD2 limits the TLR2-mediated macrophage response to peptidoglycan (PGN), whereas NOD2 variants
fail to inhibit this process, causing enhanced activation of NF-κB, particularly c-Rel, and IL-12 p35 expression. Increased IL-12 release
stimulates growth and differentiation of Th1 T cells, thereby promoting IFN-γ driven intestinal inflammation. Hypothesis III (“Enhanced IL-1β
processing,” right column) holds that variant, but not normal, NOD2 can activate IL-1β-converting enzyme (ICE/caspase-1), which converts
proIL-1β into mature 17 kDa IL-1β that is released by macrophages and contributes to intestinal inflammation through activation of a broad
range of proinflammatory genes in an autocrine or paracrine fashion. In addition, CD-associated NOD2 variants are more effective activators
of RIP2 and NF-κB.inducible NO synthase, but could also be due to a more
direct function of NOD2 such as controlling bacterial
uptake or trafficking of bacteria-containing vesicles.
Furthermore, mice lacking NOD2 altogether showed a
defect in intestinal innate defense against oral infection
with L. monocytogenes, which was paralleled by dimin-
ished expression of at least two Paneth cell-derived an-
timicrobial peptides, Defcr4 and Defcr-rs10 (Kobayashi
et al., 2005). CD patients with mutant NOD2 were
shown to have decreased expression of the human
Paneth cell α-defensins HD-5 and HD-6 in the small
intestine (Wehkamp et al., 2004), suggesting that CD-
associated NOD2 mutations may be functionally equiv-
alent to the loss of the protein in knockout mice. How-
ever, it should be noted that no NOD2 mutation that
completely abolishes protein expression or resulting in
loss of a major portion of the protein has been iden-
tified. Thus, at least genetically, the complete ablation
of NOD2 expression in Nod2−/− mice is not akin to the
situation in CD patients. Nonetheless, these observa-
tions led to the suggestion that a host carrying mutant
Immunity
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Iagainst enteric bacteria (Figure 2), which would be pre-
Mdicted to lead to bacterial overgrowth in the lumen or
sperhaps a shift in the intestinal microbiota toward more
sinflammation-causing bacteria and, thus, evoke a mu-
2cosal inflammatory response. Consistent with this hy-
Npothesis are the observations that NOD2 is expressed
aconstitutively in Paneth cells in the small intestine (Lala
iet al., 2003; Ogura et al., 2003), that NOD2 mutations
tpredispose particularly to ileal involvement in CD (Ah-
1mad et al., 2002), and that antibiotic therapy is benefi-
dcial in a subgroup of CD patients (Isaacs and Sartor,
d2004).
gThe defective epithelial defense hypothesis is plausi-
(ble, yet its current utility is limited mainly by the lack of
tdirect evidence that products of Paneth cells or entero-
mcytes control the levels of commensal microbes rele-
nvant for initiating or sustaining intestinal inflammation.
t
Mice deficient for all mature Paneth cell defensins due
l
to ablation of the critical processing enzyme matrilysin s
have no apparent intestinal pathology or bacterial over- c
growth (Wilson et al., 1999). In comparison, Nod2−/− w
mice exhibited a more limited defensin defect, with only o
modest decreases in expression of several, but not all, t
Paneth cell defensins (Kobayashi et al., 2005), ques- w
tioning the impact of these limited changes on relevant 2
antimicrobial defense in the intestine. A further concern
is that the studies on NOD2-dependent epithelial de- t
fense were conducted with the invasive and highly viru- o
lent bacteria Salmonella and Listeria, which are not h
likely to play a role in the pathogenesis of CD and p
whose interactions with the epithelium and mucosa dif- a
fer markedly from those of commensal bacteria more b
likely to contribute to disease development. The inter- t
pretation of the oral infection studies with Listeria in b
mice is further complicated by the fact that high inocula e
tare needed to achieve reliable infection due to a muta-
ation in the key bacterial receptor on epithelial cells,
tE-cadherin (Lecuit et al., 2001). Host defenses against
tsuch high inocula may not be equally important for con-
strolling physiologically relevant bacterial loads. Finally,
mantibiotic therapy is ineffective in many CD patients,
iwhich suggests that any deficiency in NOD2-depen-
Ndent Paneth cell defenses against enteric bacteria is of
Tlimited pathogenetic importance for sustaining inflam-
tmation in these patients.
dIn principle, the concept of defective antimicrobial
idefense in cells expressing NOD2 variants can also be
m
applied to macrophages, which produce NOD2 consti-
n
tutively, although no direct evidence has been reported o
that these cells exhibit diminished bacterial killing ca- c
pacity in the absence of NOD2. If mutations in NOD2 t
lead to a loss of NOD2-dependent antimicrobial activity t
in macrophages, it would suggest that NOD2 has f
essential functions in microbe detection that are not w
provided by other microbial pattern recognition recep- t
tors, particularly TLRs, which are abundantly expressed t
by macrophages. This proposition seems unlikely, how- E
ever, given that TLRs sense a diverse range of microbial M
products of both gram-negative and gram-positive a
bacteria, and TLR ligands are generally stronger NF-κB a
hactivators than NOD2 ligands (Maeda et al., 2005).L-12 Dysregulation
ncubation of normal murine splenic macrophages with
DP was shown to suppress IL-12p40 and IL-12p70
ecretion induced by stimulation with TLR2 ligands,
uch as peptidoglycan or Pam3Cys (Watanabe et al.,
004). This suppression did not occur in cells lacking
OD2, or in cells expressing a mutant form of NOD2
fter transfection. A similar mechanism appeared to act
n vivo since systemic administration of peptidoglycan
o Nod2−/− mice induced more serum IL-12p40 and IL-
2p70 compared to wild-type mice. Further analysis in-
icated that increased IL-12p70 production in pepti-
oglycan-stimulated NOD2-deficient cells was due to
reater c-Rel-dependent IL-12p35 mRNA expression
Watanabe et al., 2004). Together, these data suggest
hat inactivation of NOD2 enhances IL-12 secretion in
acrophages because NOD2 normally limits TLR2 ago-
ist-stimulated expression of this cytokine (Figure 2). In
his scenario, NOD2 variants lack an inhibitory function,
eading to an overall increase in IL-12 production. Once
ecreted, IL-12 promotes IFN-γ production by T and NK
ells and growth and differentiation of Th1-type T cells,
hich are thought to be important in the pathogenesis
f CD (Bouma and Strober, 2003). Consistent with this,
reatment of CD patients with antibodies against IL-12
as recently shown to be effective (Mannon et al.,
004).
A major current concern about the IL-12 dysregula-
ion hypothesis is the reproducibility of the underlying
bservations, as another group did not observe en-
anced IL-12 secretion by NOD2-deficient macro-
hages in response to TLR2 engagement (Kobayashi et
l., 2005). It is possible that differences in the genetic
ackground of the mouse strains or critical details of
he experimental design account for the discrepancy,
ut this remains to be resolved. Furthermore, the IL-12-
nhancing effects of the NOD2 deficiency were limited
o signaling via TLR2, but not other TLRs (Watanabe et
l., 2004). This suggests that TLR2 would be expected
o be uniquely capable of promoting colonic inflamma-
ion under conditions of NOD2 deficiency, yet other
tudies have shown that TLR2, at least in wild-type
ice, mediates protective functions in experimentally
nduced colitis (Rachmilewitz et al., 2004; Rakoff-
ahoum et al., 2004). The selective effect of NOD2 on
LR2 signaling would also suggest that TLR2 signals
o NF-κB, particularly c-Rel, through a mechanism that
iffers from that of other TLRs or that NOD2 directly
nteracts with a specific site within the cytoplasmic do-
ain of TLR2 that is not shared with other TLRs, but
o data exist so far to support either hypothesis. More-
ver, costimulation of peripheral blood mononuclear
ells from CD patients homozygous for the 1007fs mu-
ation with MDP and TLR2 ligands was shown to lead
o a loss, not gain, of synergistic induction of the proin-
lammatory cytokines TNFβ and IL-1β compared to
ild-type cells (van Heel et al., 2005), thus questioning
he applicability of the results obtained in Nod2−/− mice
o human CD.
nhanced IL-1b Processing
acrophages of mice homozygous for a mutant Nod2
llele (Nod22939iC) equivalent to the most common CD-
ssociated allele (3020insC) were shown to secrete
igher levels of the mature form of IL-1β and have ele-
Review
665vated IL-1β mRNA levels, as well as increased IKK and
NF-κB activities, upon stimulation with MDP relative to
wild-type macrophages but retain normal responses to
TLR ligands (Maeda et al., 2005). In parallel, these mice
exhibited greater colonic inflammation upon experi-
mental challenge with dextran sulfate sodium, a pheno-
type that was attenuated by treatment with an inhibitor
of IL-1 signaling, IL-1 receptor antagonist (IL-1Ra) (Maeda
et al., 2005). These results suggest that the variant
NOD2 protein expressed in these mice promotes pro-
cessing of proIL-1β to mature, biologically active, IL-1β
(Figure 2). Given that IL-1β converting enzyme (ICE,
also termed caspase-1) is critical for this processing
step, it is reasonable to assume that the variant NOD2
can activate ICE either directly or indirectly in response
to MDP, thereby identifying the 2939iC/3020insC muta-
tions as gain-of-function mutations. An attractive ICE
activation mechanism may involve the CARD domains
of NOD2, which might interact with matching domains
in ICE, analogous to interactions reported for NOD1
(Yoo et al., 2002). Elevated IL-1β secretion by Nod22939iC
macrophages may also be due to an effect of NOD2 on
macrophage survival, as normal macrophages secrete
very little mature IL-1β in response to proinflammatory
stimuli, such as LPS, unless induced to undergo apo-
ptosis (Hogquist et al., 1991). Enhanced IL-1β release
can subsequently induce expression of multiple proin-
flammatory cytokines and other mediators in an au-
tocrine or paracrine fashion, leading to a greater inflam-
matory response in the intestine. Consistent with a role
of IL-1β in regulating colitis, mice deficient in ICE have
reduced inflammation in an experimental colitis model
(Siegmund et al., 2001), and IL-1β expression and
secretion are markedly increased in the mucosa of CD
patients, whereas IL-1Ra expression is often reduced
(McAlindon et al., 1998). Further consistent with the
gain-of-function nature of the IL-1β-processing hypoth-
esis is that heterozygosity for a single NOD2 mutation
confers a significant (2- to 4-fold) increase in CD risk
(Economou et al., 2004). In addition to IL-1β activation,
it is possible that CD-linked NOD2 variants can activate
the downstream protein kinase RIP2 more effectively
than the normal protein. This kinase is strongly acti-
vated during experimentally induced intestinal inflam-
mation, and inhibition of its activity is accompanied by
attenuation of inflammation (Hollenbach et al., 2005).
The IL-1β processing hypothesis is strongly sup-
ported by mouse model data, but its applicability to
understanding human CD is not entirely clear at pres-
ent. Unlike the observations made with macrophages
from Nod22939iC mutant mice, monocyte-derived ma-
crophages from two CD patients homozygous for the
3020insC mutation of NOD2 were shown to have re-
duced NF-κB activation and IL-1β mRNA expression
and release upon MDP stimulation (Li et al., 2004).
However, as mentioned above, these cells were derived
from the peripheral blood of patients with active inflam-
mation, which might have altered subsequent respon-
siveness to microbial products. Transfection of mutant
NOD2 alleles into epithelial cells has resulted in variant
proteins that no longer respond to MDP or activate NF-
κB, but this was done under overexpression conditions
(Bonen et al., 2003). The reasons for the apparent
discrepancy between the effects of NOD2 mutations onNF-κB activation and IL-1β expression and processing
in mouse and human cells are not readily apparent. It
is possible that the technical details of the cell prepara-
tion and stimulation conditions may be important or
that relevant differences exist between NOD2 signaling
in human and mouse cells. In addition, it is formally
possible that the variant NOD2 proteins are relatively
unstable in human cells, resulting in a loss-of-function
effect, whereas they are stable in mouse cells. Detailed
analysis of the effect of NOD2 mutations on the stability
of the corresponding proteins in cells isolated from CD
patients has not been performed but is obviously
needed for assessing this possibility. Finally, it is con-
ceivable that the CD-associated human, but not mouse,
NOD2 variants have lost their ability to respond to MDP,
but the variants from both species can respond more
strongly to other, yet-to-be-discovered microbe- or
host-derived molecules that play a role in initiating or
sustaining an intestinal inflammatory response. Identifi-
cation of potential NOD2 activators other than MDP
would be an important step toward testing this notion.
Future Directions
The association of NOD2 mutations with CD in Western
populations is now firmly established, and several
promising hypotheses to explain this association have
been advanced. More basic and clinical research is
needed to assess the relative importance of these
hypotheses for understanding the pathogenesis of CD.
Murine studies will likely continue to provide unique op-
portunities to determine the pathophysiological signifi-
cance of NOD2 mutations in complex in vivo models.
For example, mice can be generated and characterized
that have different targeted mutations in the Nod2 locus
corresponding to the broad spectrum of CD-associated
mutations found in humans, as well as mutations linked
to other inflammatory disorders. Such mice should be
challenged in different intestinal inflammation models,
particularly those where an acute, nonspecific inflam-
matory response progresses into chronic T cell-medi-
ated inflammation and which reflect other key pathoge-
netic aspects of human IBD. Defined cell populations
of such mice can be obtained and studied in vitro for
the effects of the mutations on signal transduction.
Hypotheses and predictions developed in murine studies
need to be validated and complemented by studies
with human cells and tissues from IBD patients and
healthy individuals, both with wild-type and mutant
NOD2 alleles. Clinically, it will be of interest to deter-
mine the relationship between NOD2 gene status and
the efficacy of antibiotic treatment in CD, as it may pro-
vide insights into the relative contribution of enteric
bacteria as an ongoing stimulus for sustaining the mu-
cosal inflammatory response. Furthermore, evaluation
of the potential impact of blocking ICE, IL-1, or RIP2
signaling in IBD patients, with and without NOD2 muta-
tions, would be of interest and may lead to new thera-
pies. In this respect, it should be noted that future work
will require improved IL-1 antagonists as the pharma-
codynamic profile of IL-1Ra is compromised by its lim-
ited stability.
Immunity
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